Floatz logo

Idarubicine

Child-Pugh Class A

Stanford UniversityPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Child-Pugh Class A cohort.

Asset / SponsorPhaseRating
Raltitrexed
Stanford University
Phase 3BB
Inno-206
Stanford University
Phase 3BB
Eloxatin
Stanford University
Phase 3BB
Ethiodized Oil
Stanford University
Phase 3B
Pembrolizumab
Roswell Park Cancer Institute
Phase 1/2CCC
Sorafenib
Roswell Park Cancer Institute
Phase 1/2CCC
Epirubicin
Roswell Park Cancer Institute
Phase 1/2CCC
Cyclophosphamide
Roswell Park Cancer Institute
Phase 1/2CCC

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →